{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T09:52:41Z","timestamp":1790502761875,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.yebeh.2021.108493","type":"journal-article","created":{"date-parts":[[2021,12,18]],"date-time":"2021-12-18T12:09:36Z","timestamp":1639829376000},"page":"108493","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Differences in aggression as psychiatric side effect of levetiracetam and perampanel in patients with epilepsy"],"prefix":"10.1016","volume":"126","author":[{"given":"Mihoko","family":"Kawai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Goji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kousuke","family":"Kanemoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2021.108493_b0005","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1212\/01.WNL.0000103282.62353.85","article-title":"Depression but not seizure frequency predicts quality of life in treatment-resistant epilepsy","volume":"62","author":"Boylan","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2021.108493_b0010","doi-asserted-by":"crossref","DOI":"10.1111\/j.1528-1167.2007.01222.x","article-title":"Psychiatric comorbidity in epilepsy: a population-based analysis","volume":"48","author":"Tellez-Zenteno","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.108493_b0015","doi-asserted-by":"crossref","unstructured":"Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS, Progress report on new antiepileptic drugs: a summary of the Thirteenth Eilat Conference on New Antiepileptic Drugs and Devices. (EILAT XIII) Epilepsia 2017;58 (2);181-221","DOI":"10.1111\/epi.13634"},{"issue":"1","key":"10.1016\/j.yebeh.2021.108493_b0020","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.yebeh.2006.08.008","article-title":"Psychiatric and behavioral side effects of the newer antiepileptic drugs in adults with epilepsy","volume":"10","author":"Weintraub","year":"2007","journal-title":"Epilepsy Behav"},{"issue":"3","key":"10.1016\/j.yebeh.2021.108493_b0025","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/j.1528-1167.2008.01792.x","article-title":"Effects of lamotrigine compared with levetiracetam on anger, hostility, and total mood in patients with partial epilepsy","volume":"50","author":"Labiner","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.108493_b0030","doi-asserted-by":"crossref","unstructured":"Steinhoff BJ, Ben-Menachem E, Ryvlin P, Shorvon S, Kramer L, Satlin A, et al. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies. Epilepsia. 2013;4(8):1481-9.","DOI":"10.1111\/epi.12212"},{"issue":"8","key":"10.1016\/j.yebeh.2021.108493_b0035","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1111\/epi.13054","article-title":"Psychiatric and behavioral adverse events in randomized clinical studies of the noncompetitive AMPA receptor antagonist perampanel","volume":"56","author":"Ettinger","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.108493_b0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.seizure.2019.02.009","article-title":"The effect of perampanel on aggression and depression in patients with epilepsy: A short-term prospective study","volume":"67","author":"Goji","year":"2019","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2021.108493_b0045","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1212\/WNL.0000000000001930","article-title":"Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy A randomized trial","volume":"85","author":"French","year":"2015","journal-title":"Neurology"},{"issue":"18","key":"10.1016\/j.yebeh.2021.108493_b0050","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1212\/WNL.0b013e318254473a","article-title":"Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures","volume":"78","author":"Krauss","year":"2012","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.yebeh.2021.108493_b0055","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s40263-013-0091-9","article-title":"Systematic review and meta-analysis of the efficacy and safety of perampanel in the treatment of partial-onset epilepsy","volume":"27","author":"Hsu","year":"2013","journal-title":"CNS Drugs"},{"key":"10.1016\/j.yebeh.2021.108493_b0060","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/epi.13709","article-title":"ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Scheffer","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.108493_b0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yebeh.2020.107546","article-title":"Aggression as psychiatric side-effect of newer AEDs in patients with epilepsy: Cross-sectional study based on Buss-Perry Aggression Questionnaire","volume":"115","author":"Kawai","year":"2021","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2021.108493_b0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2018\/2064027","article-title":"Mechanisms underlying aggressive behavior induced by antiepileptic drugs: focus on topiramate, levetiracetam, and perampanel","volume":"2018","author":"Hansen","year":"2018","journal-title":"Behav Neurol"},{"issue":"3","key":"10.1016\/j.yebeh.2021.108493_b0075","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.yebeh.2008.05.012","article-title":"Positive and negative psychotropic effects of levetiracetam","volume":"13","author":"Helmstaedter","year":"2008","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2021.108493_b0080","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.yebeh.2018.01.001","article-title":"Efficacy and tolerability of perampanel and levetiracetam as first add-on therapy in patients with epilepsy: A retrospective single center study","volume":"80","author":"Liguori","year":"2018","journal-title":"Epilepsy Behav"},{"issue":"3","key":"10.1016\/j.yebeh.2021.108493_b0085","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1037\/0022-3514.63.3.452","article-title":"The aggression questionnaire","volume":"63","author":"Buss","year":"1992","journal-title":"J Person Soc Psychol"},{"key":"10.1016\/j.yebeh.2021.108493_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.107806","article-title":"Levetiracetam, perampanel, and the issue of aggression: A self-report study","volume":"117","author":"von Wrede","year":"2021","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2021.108493_b0095","doi-asserted-by":"crossref","first-page":"107644","DOI":"10.1016\/j.yebeh.2020.107644","article-title":"Differences in levetiracetam and perampanel treatment-related irritability in patients with epilepsy","volume":"116","author":"Hasegawa","year":"2021","journal-title":"Epilepsy Behav"},{"issue":"2","key":"10.1016\/j.yebeh.2021.108493_b0100","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.yebeh.2011.03.015","article-title":"Lamotrigine improves aggression in patients with temporal lobe epilepsy","volume":"21","author":"Kato","year":"2011","journal-title":"Epilepsy Behav"},{"issue":"5","key":"10.1016\/j.yebeh.2021.108493_b0105","doi-asserted-by":"crossref","first-page":"384","DOI":"10.4992\/jjpsy.70.384","article-title":"Development of the Japanese version of the Buss-Perry Aggression Questionnaire (BAQ)","volume":"70","author":"Ando","year":"1999","journal-title":"Jpn J Psychol"},{"issue":"7","key":"10.1016\/j.yebeh.2021.108493_b0110","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S0005-7967(00)00057-7","article-title":"Psychometric evaluation on the Japanese adaptation of the Aggression Questionnaire","volume":"39","author":"Nakano","year":"2001","journal-title":"Behav Res Ther"},{"key":"10.1016\/j.yebeh.2021.108493_b0115","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.yebeh.2017.06.038","article-title":"Perampanel with concomitant levetiracetam and topiramate: Post hoc analysis of adverse events related to hostility and aggression","volume":"75","author":"Chung","year":"2017","journal-title":"Epilepsy Behav"},{"issue":"3","key":"10.1016\/j.yebeh.2021.108493_b0120","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1124\/pr.115.012021","article-title":"Epilepsy, antiepileptic drugs, and aggression: an evidence-based review","volume":"68","author":"Brodie","year":"2016","journal-title":"Pharmacol Rev"},{"issue":"9","key":"10.1016\/j.yebeh.2021.108493_b0125","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.jpsychires.2013.05.001","article-title":"Cerebrospinal fluid glutamate concentration correlates with impulsive aggression in human subjects","volume":"47","author":"Coccaro","year":"2013","journal-title":"J Psychiatr Res"},{"issue":"6","key":"10.1016\/j.yebeh.2021.108493_b0130","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.4103\/0028-3886.193801","article-title":"Levetiracetam as an antiepileptic, neuroprotective, and hyperalgesic drug","volume":"64","author":"Cortes-Altamirano","year":"2016","journal-title":"Neurology India"},{"key":"10.1016\/j.yebeh.2021.108493_b0135","doi-asserted-by":"crossref","first-page":"9861","DOI":"10.1073\/pnas.0308208101","article-title":"The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam","volume":"101","author":"Lynch","year":"2004","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152550502100754X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152550502100754X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:42:01Z","timestamp":1761504121000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152550502100754X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":27,"alternative-id":["S152550502100754X"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2021.108493","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Differences in aggression as psychiatric side effect of levetiracetam and perampanel in patients with epilepsy","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2021.108493","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108493"}}